News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
888,131 Results
Type
Article (89109)
Company Profile (552)
Press Release (798454)
Multimedia
Podcasts (254)
Webinars (37)
Section
Business (267177)
Career Advice (4168)
Deals (40062)
Drug Delivery (187)
Drug Development (91858)
Employer Resources (208)
FDA (18638)
Job Trends (17512)
News (399074)
Policy (40029)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (4)
2027 Genetown Standard (7)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (7)
Academia (3073)
Academic (2)
Accelerated approval (63)
ADA (50)
Adcomms (43)
Allergies (216)
Alliances (56990)
ALS (252)
Alzheimer's disease (2062)
Antibody-drug conjugate (ADC) (624)
Approvals (19075)
Artificial intelligence (964)
ASCO (345)
Autoimmune disease (407)
Automation (69)
Bankruptcy (409)
Best Places to Work (12635)
BIO (81)
Biologics (1)
BIOSECURE Act (23)
Biosimilars (273)
BioSpace Insights (238)
Biotechnology (337)
Bladder cancer (227)
Brain cancer (87)
Breast cancer (885)
Cancer (7024)
Cardiovascular disease (598)
Career advice (3610)
Career pathing (57)
CAR-T (408)
CDC (77)
Celiac Disease (3)
Cell therapy (1134)
Cervical cancer (60)
Clinical research (79685)
Collaboration (2569)
Commercialization (6)
Company closure (8)
Compensation (1676)
Complete response letters (120)
COVID-19 (3054)
CRISPR (132)
C-suite (1442)
Cystic fibrosis (173)
Data (9284)
Decentralized trials (3)
Denatured (98)
Depression (211)
Dermatology (117)
Diabetes (743)
Diagnostics (7732)
Digital health (77)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (494)
Drug pricing (248)
Drug shortages (39)
Duchenne muscular dystrophy (353)
Earnings (103320)
Editorial (82)
Employer branding (25)
Employer resources (178)
Events (139317)
Executive appointments (1276)
FDA (23097)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (25)
Frontotemporal dementia (37)
Funding (2087)
Gene editing (290)
Generative AI (99)
Gene therapy (894)
GLP-1 (1320)
Government (5577)
Grass and pollen (8)
Guidances (434)
Healthcare (21291)
Hematology (198)
HIV (110)
Huntington's disease (74)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (127)
Immunology and inflammation (381)
Immuno-oncology (126)
Indications (239)
Infectious disease (3474)
Inflammatory bowel disease (249)
Inflation Reduction Act (17)
Influenza (157)
Intellectual property (349)
Interviews (824)
IPO (18033)
IRA (61)
Job creations (5209)
Job search strategy (2876)
JPM (73)
Kidney cancer (27)
Labor market (131)
Layoffs (704)
Leadership (57)
Legal (10174)
Licensing (12)
Liver cancer (112)
Longevity (38)
Lung cancer (931)
Lymphoma (507)
Machine learning (70)
Management (69)
Manufacturing (1366)
Marketing (13)
MASH (234)
Medical affairs (1)
Medical device (15357)
Medtech (15590)
Mergers & acquisitions (23444)
Metabolic disorders (1922)
mRNA (287)
Multiple sclerosis (218)
NASH (24)
Neurodegenerative disease (561)
Neuropsychiatric disorders (138)
Neuroscience (3965)
Neurotech (2)
NextGen: Class of 2026 (7717)
Non-profit (5154)
Now hiring (88)
Obesity (910)
Opinion (385)
Ovarian cancer (259)
Pain (303)
Pancreatic cancer (385)
Parkinson's disease (445)
Partnered (44)
Patents (720)
Patient recruitment (889)
Peanut (73)
People (68407)
Pharmaceutical (81)
Pharmacy benefit managers (38)
Phase 1 (24607)
Phase 2 (34608)
Phase 3 (26030)
Pipeline (11256)
Policy (411)
Postmarket research (3561)
Preclinical (11031)
Press Release (72)
Prostate cancer (372)
Psychedelics (85)
Radiopharmaceuticals (393)
Rare diseases (1405)
Real estate (7467)
Recruiting (83)
Regulatory (30976)
Reports (83)
Research institute (2789)
Resumes & cover letters (655)
Rett syndrome (50)
RNA editing (32)
RSV (101)
Schizophrenia (204)
Series A (356)
Series B (261)
Service/supplier (16)
Sickle cell disease (136)
Special edition (34)
Spinal muscular atrophy (194)
Sponsored (55)
Startups (4379)
State (2)
Stomach cancer (21)
Supply chain (153)
Tariffs (105)
The Weekly (153)
Vaccines (1355)
Venture capital (146)
Weight loss (618)
Women's health (155)
Worklife (25)
Date
Today (144)
Last 7 days (808)
Last 30 days (2591)
Last 365 days (33480)
2026 (20797)
2025 (33208)
2024 (37830)
2023 (42564)
2022 (53928)
2021 (58720)
2020 (57663)
2019 (51334)
2018 (39119)
2017 (37188)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1300)
Alabama (107)
Alaska (7)
Arizona (432)
Arkansas (16)
Asia (52597)
Australia (9251)
California (15248)
Canada (4251)
China (1734)
Colorado (657)
Connecticut (676)
Delaware (470)
Europe (121315)
Florida (2306)
Georgia (494)
Hawaii (5)
Idaho (70)
Illinois (1329)
India (121)
Indiana (702)
Iowa (26)
Japan (658)
Kansas (149)
Kentucky (59)
Louisiana (66)
Maine (93)
Maryland (1827)
Massachusetts (11138)
Michigan (438)
Minnesota (853)
Mississippi (7)
Missouri (173)
Montana (37)
Nebraska (31)
Nevada (161)
New Hampshire (92)
New Jersey (4025)
New Mexico (37)
New York (4014)
North Carolina (2006)
North Dakota (11)
Northern California (7661)
Ohio (479)
Oklahoma (29)
Oregon (48)
Pennsylvania (2964)
Puerto Rico (33)
Rhode Island (55)
South America (1671)
South Carolina (92)
South Dakota (2)
Southern California (6029)
Tennessee (252)
Texas (2482)
United States (54374)
Utah (465)
Vermont (2)
Virginia (384)
Washington D.C. (87)
Washington State (1231)
West Virginia (4)
Wisconsin (169)
Wyoming (2)
888,131 Results for "%E2%80%9D%20target=".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
August 10, 2026
·
7 min read
Press Releases
Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer
July 28, 2026
·
6 min read
Business
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
July 22, 2026
·
4 min read
·
Nick Paul Taylor
Press Releases
Life Biosciences Secures $80 Million Series D Financing
April 8, 2026
·
3 min read
Press Releases
E2 (Endovascular Engineering) Raises $80 Million Series C to Advance Next-Generation Thrombectomy Platform as Pulmonary Embolism Treatment Evolves
April 7, 2026
·
3 min read
Press Releases
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
July 23, 2026
·
10 min read
Press Releases
Akeso’s Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
June 15, 2026
·
6 min read
Press Releases
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
July 29, 2026
·
10 min read
RNA editing
Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B
For an investment of up to $1.9 billion, Eli Lilly will be able to use Ascidian Therapeutics’ platform that removes mutated exons from mRNA molecules, avoiding the expression of disease-causing proteins.
June 3, 2026
·
2 min read
·
Tristan Manalac
Obesity
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
With weight loss topping 20% at 80 weeks in the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, Eli Lilly plans to file for retatrutide’s approval in the first quarter of 2027. Previously a filing was expected later this year.
July 23, 2026
·
3 min read
·
Tristan Manalac
1 of 88,814
Next